ABEO
Abeona Therapeutics Inc.
Company Overview
| Mkt Cap | $217.93M | Price | $5.45 |
| Volume | 402.54K | Change | +0.09% |
| P/E Ratio | 3.1 | Open | $5.49 |
| Revenue | $5.8M | Prev Close | $5.44 |
| Net Income | $71.2M | 52W Range | $4.00 - $7.54 |
| Div Yield | N/A | Target | $19.71 |
| Overall | 60 | Value | 80 |
| Quality | 39 | Technical | 63 |
No chart data available
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Latest News
Kepler Capital Remains a Buy on Abeo SA (4A8)
Abeona Therapeutics (ABEO) Gets a Buy from Oppenheimer
Analysts Are Bullish on These Healthcare Stocks: Abeona Therapeutics (ABEO), Protara Therapeutics (TARA)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABEO | $5.45 | +0.1% | 402.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Abeona Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW